Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
TJ-034 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
TJ-034: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Lu AH69593 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Lu AH69593: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Multi-epitope HER2 peptide vaccine(Mayo Clinic) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Multi-epitope HER2 peptide vaccine(Mayo Clinic): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market
9 min read
Palmidrol/Pregabalin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Palmidrol/Pregabalin: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Rimeporide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Rimeporide: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PJ-019 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
PJ-019: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
LY03009 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
LY03009: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
CD19CAR-28-zeta T cells Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CD19CAR-28-zeta T cells: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
DXC-1002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
DXC-1002: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
[68]Ga-OncoCAlX Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
[68]Ga-OncoCAlX: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BI-1323495 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BI-1323495: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BTX-9341 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BTX-9341: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.